- Home
- MMA vs KPRX Comparison
MMA vs KPRX Comparison
Compare MMA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | KPRX |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | Australia | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MMA | KPRX |
|---|---|---|
| Price | $0.57 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 209.1K | 48.7K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $1.76 |
| 52 Week High | $2.00 | $3.29 |
Technical Indicators
Market Signals| Indicator | MMA | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 42.78 |
| Support Level | $0.35 | $2.24 |
| Resistance Level | $0.58 | $2.51 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 79.66 | 0.00 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.